Biofourmis’ FDA-cleared software-as a-medical-device Biovitals® enables care teams to remotely monitor the physiological signs of patients in both acute and post-acute settings and provides clinical teams with a real-time look at patients' disease trajectory, which helps identify clinical decompensation at an earlier stage to prevent serious medical adverse events before they occur.
The most recent addition to the Biovitals® platform, Hospital@HomeTM, is an end-to-end solution that enables hospitals and health systems to quickly deploy a home hospital program that delivers inpatient-level care within patients' homes. It includes clinical care services and non-clinical services such as program management, operations, supply chain and revenue cycle management. In late 2020, the Centers for Medicare and Medicaid Services (CMS) announced reimbursement parity with inpatient care for health systems offering hospital at home programs. Biofourmis originally co-developed Biovitals® Hospital@Home™ with Brigham and Women's Hospital, a Harvard teaching hospital, for use in Brigham’s Home Hospital Program.
Ad Statistics
Times Displayed: 114080
Times Visited: 6783 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
About Biofourmis
Biofourmis is a global leader in virtual care and digital therapeutics, offering innovative solutions that enable clinicians to deliver personalized predictive care to patients outside of a traditional hospital, clinic, or clinical research environment. Biovitals®, a highly sophisticated AI-powered health analytics platform, utilizes medical-grade wearables to continuously collect patient data to predict clinical exacerbation in advance of a critical event, which enables earlier interventions and leads to better clinical and financial outcomes. The Biovitals platform is in use across multiple therapeutic areas for acute and chronic conditions, including heart failure, oncology, infectious disease such as COVID-19, chronic pain, and COPD, and is prescribed as a companion digital therapeutic with pharmacotherapy in pay-for-value arrangements. For more information, visit: www.biofourmis.com and follow us on LinkedIn and Twitter.
Back to HCB News
